Scarica l'app Stockscreener
36.30
1.04%
-0.38
Ideaya Biosciences Inc Borsa (IDYA) Ultime notizie
Bank of America Corp DE Has $31.39 Million Stake in IDEAYA Biosciences, Inc. $IDYA - MarketBeat
Walleye Capital LLC Buys Shares of 386,183 IDEAYA Biosciences, Inc. $IDYA - MarketBeat
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
IDEAYA Biosciences (NASDAQ:IDYA) Rating Lowered to "Sell" at Wall Street Zen - MarketBeat
Baker Bros. Advisors (IDYA) reports 5.2% IDEAYA stake and capped warrants - Stock Titan
J.P. Morgan Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Cuts Target Price to $62 - Moomoo
IDEAYA Biosciences (IDYA) Short Interest & Short Float | Updated Aug 2026 - MarketBeat
How (IDYA) Movements Inform Risk Allocation Models - news.stocktradersdaily.com
IDEAYA Biosciences (NASDAQ:IDYA) Displays Perfect Technical Strength and Breakout Setup - ChartMill
LifeSci Capital Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $58 - Moomoo
IDEAYA Biosciences Inc (IDYA) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
IDEAYA Biosciences (NASDAQ:IDYA) Is In A Strong Position To Grow Its Business - Moomoo
RBC Capital Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $48 - Moomoo
The Bull Case For IDEAYA Biosciences (IDYA) Could Change Following Wider Loss And New Roche Partnership - Yahoo Finance
IDEAYA Biosciences (NASDAQ:IDYA) Given New $59.00 Price Target at Truist Financial - MarketBeat
Truist Financial Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Cuts Target Price to $59 - Moomoo
A Quick Look at Today's Ratings for IDEAYA Biosciences(IDYA.US), With a Forecast Between $48 to $60 - Moomoo
IDEAYA BIOSCIENCES, INC. : LEERINK PARTNERS CUTS TARGET PRICE TO $31 FROM $37 - Bitget
IDEAYA Biosciences 2Q 2026: Revenue $8.86M, EPS $(1.22) — 10-Q Summary - TradingView
IDEAYA Biosciences (NASDAQ: IDYA) reports $1.24B cash and rising R&D spend - stocktitan.net
IDEAYA Biosciences (NASDAQ:IDYA) Releases Quarterly Earnings Results, Misses Estimates By $0.16 EPS - MarketBeat
IDEAYA Biosciences Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Earnings Flash (IDYA) IDEAYA Biosciences, Inc. Reports Q2 Revenue $8.9M, vs. FactSet Est of $8.0M - marketscreener.com
IDEAYA Posts Q2 Loss as Cash Reaches $1.24 Billion - Quiver Quantitative
IDEAYA Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update - PR Newswire
IDEAYA Biosciences (IDYA) Stock Analysis: Unpacking a 51% Potential Upside with Strong Buy Ratings - DirectorsTalk Interviews
IDEAYA Biosciences (IDYA) Expected to Post Earnings on Monday - MarketBeat
Seven Fleet Capital Management LP Buys New Position in IDEAYA Biosciences, Inc. $IDYA - MarketBeat
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance Singapore
14 New IDEAYA Hires Granted Stock Options at $36.40 - Stock Titan
IDEAYA Biosciences, Inc. $IDYA Shares Sold by Redmile Group LLC - MarketBeat
SummitTX Capital L.P. Purchases New Holdings in IDEAYA Biosciences, Inc. $IDYA - MarketBeat
LifeSci Capital Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $62 - Moomoo
IDEAYA initiates expansion phase for cancer drug IDE892 By Investing.com - Investing.com Canada
IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates Part 2 Monotherapy Expansion in the Phase 1/2 Study in MTAP-Deleted Pancreatic and Lung Cancers - PR Newswire
IDEAYA expands cancer trial after IDE892 reaches target exposure - Stock Titan
IDEAYA Biosciences Inc (IDYA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
IDEAYA Biosciences Inc (IDYA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
IDEAYA Biosciences Inc (IDYA) Valuation: PE, PB & Fair Value Analysis - TradingKey
IDEAYA Biosciences Inc (IDYA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
IDEAYA Biosciences Inc (IDYA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
IDEAYA Biosciences Inc (IDYA) Institutional Confidence - TradingKey
IDEAYA Biosciences Inc (IDYA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
IDEAYA Biosciences Inc (IDYA) Balance Sheet - TradingKey
IDYA|IDEAYA Biosciences Inc|Price:35.400|Chg%:-0.830 - TradingKey
IDYA|IDEAYA Biosciences Inc|Price:36.030|Chg%:-0.200 - TradingKey
ETFs Investing in IDEAYA Biosciences, Inc. Stocks - TradingView
IDEAYA Biosciences (IDYA) Stock Analysis: Exploring A 47.49% Upside Potential - DirectorsTalk Interviews
How Ideaya Biosciences Inc. (IDYA) Affects Rotational Strategy Timing - Stock Traders Daily
IDEAYA Biosciences Announces ESMO 2026 Presentations for Darovasertib and IDE849 Clinical Programs - BioSpace
IDEAYA Biosciences to present new clinical tria... - Pluang
Ideaya Biosciences chief accounting officer sells $382,130 in stock - Investing.com
Ideaya Biosciences chief accounting officer sells $382,130 in stock By Investing.com - Investing.com Nigeria
Form 4 Ideaya Biosciences Inc For: 9 July By Investing.com - Investing.com Nigeria
Ideaya Biosciences Insider Sold Shares Worth $382,131, According to a Recent SEC Filing - Moomoo
IDEAYA Biosciences (IDYA) CAO exercises options, sells 9,550 pre-planned shares - Stock Titan
Ideaya Biosciences highlights its precision oncology pipeline as Nasdaq-listed cancer drug developer - Ad-hoc-news.de
IDEAYA Biosciences and Servier Provide Complete Data from Phase 2/3 Registrational OptimUM-02 Trial of the Darovasertib Combination in First Line HLA*A2:01 Negative Metastatic Uveal Melanoma in a Late-Breaking Oral Presentation at ASCO - AOL.com
Form 144 IDEAYA Biosciences For: 7 July By Investing.com - Investing.com South Africa
[144] IDEAYA Biosciences, Inc. SEC Filing - Stock Titan
Truist Financial Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Announces Target Price $63 - Moomoo
RBC Capital Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Cuts Target Price to $48 - Moomoo
0.52%
0.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):